Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Once-Monthly Injectable Abilify Maintena Approved in Canada: Otsuka, Lundbeck
February 17, 2014
- New Suspicion Hints Close Link between Novartis, SIGN Initiator Group
February 17, 2014
- Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
- Qol to Introduce Bidding System for Drug Purchasing Aimed at Avoiding Reduction in Basic Dispensing Fees Received
February 14, 2014
- Ex-Bellsystem24 Exec Deguchi to Spearhead AbbVie Japan
February 13, 2014
- Kyowa Kirin Temporarily Drops Untreated ATL Indication for Poteligeo
February 13, 2014
- Kaken Licenses Container Technology for Efinaconazole to Valeant
February 13, 2014
- AnGes Sales Up 10.5% but Logs 1,409 Million Yen Net Loss in 2013
February 12, 2014
- Ethical Drug Sales Up 4.7% in December: Crecon Report
February 12, 2014
- Asahi Kasei Pharma Completes 2nd Manufacturing Facility at Nagoya Pharmaceuticals Plant
February 12, 2014
- Novartis Appoints Former Tokyo High Court Judge to Head Independent Commission to Investigate Scandal Over SIGN Study
February 10, 2014
- Transdermal Parkinson’s Disease Treatment Ropinirole Shows Significant Difference in PII Study: Hisamitsu
February 10, 2014
- Mitsubishi Chemical to Set Up New Healthcare Firm
February 7, 2014
- MTPC Appoints Development Division Manager as New Representative Director
February 7, 2014
- Takeda CFO Says Midterm Strategy Not Affected by Halt of TAK-875 Trials
February 7, 2014
- Astellas to Bring Global Development, Regulatory Affairs Functions Under Control of Chief Medical Officer
February 7, 2014
- JCR, GSK Ink Research Support Agreement to Establish New Technology
February 6, 2014
- Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
- Fujifilm Pharma Gets Japan Distribution Rights for Sosei’s Oropharyngeal Candidiasis Drug
February 6, 2014
- Kyowa Kirin Begins Japan PIII Trial of ARQ 197 for Hepatocellular Cancer
February 6, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…